JP2014534245A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014534245A5 JP2014534245A5 JP2014542594A JP2014542594A JP2014534245A5 JP 2014534245 A5 JP2014534245 A5 JP 2014534245A5 JP 2014542594 A JP2014542594 A JP 2014542594A JP 2014542594 A JP2014542594 A JP 2014542594A JP 2014534245 A5 JP2014534245 A5 JP 2014534245A5
- Authority
- JP
- Japan
- Prior art keywords
- capsid
- viral
- viral vector
- aav
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000000234 capsid Anatomy 0.000 claims description 237
- 239000013603 viral vector Substances 0.000 claims description 172
- 239000000203 mixture Substances 0.000 claims description 90
- 230000003612 virological effect Effects 0.000 claims description 79
- 238000009472 formulation Methods 0.000 claims description 78
- 238000000034 method Methods 0.000 claims description 68
- 210000004027 cell Anatomy 0.000 claims description 56
- 108090000565 Capsid Proteins Proteins 0.000 claims description 55
- 102100023321 Ceruloplasmin Human genes 0.000 claims description 55
- 108700019146 Transgenes Proteins 0.000 claims description 47
- 230000028993 immune response Effects 0.000 claims description 26
- 239000013607 AAV vector Substances 0.000 claims description 25
- 108090000623 proteins and genes Proteins 0.000 claims description 24
- 239000012472 biological sample Substances 0.000 claims description 21
- 108010039209 Blood Coagulation Factors Proteins 0.000 claims description 20
- 102000015081 Blood Coagulation Factors Human genes 0.000 claims description 20
- 239000003114 blood coagulation factor Substances 0.000 claims description 20
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 16
- 235000018102 proteins Nutrition 0.000 claims description 16
- 102000004169 proteins and genes Human genes 0.000 claims description 16
- 241000700605 Viruses Species 0.000 claims description 14
- 238000010790 dilution Methods 0.000 claims description 12
- 239000012895 dilution Substances 0.000 claims description 12
- 210000003205 muscle Anatomy 0.000 claims description 12
- 210000002966 serum Anatomy 0.000 claims description 12
- 239000000523 sample Substances 0.000 claims description 11
- 239000013598 vector Substances 0.000 claims description 11
- 108010054218 Factor VIII Proteins 0.000 claims description 10
- 102000001690 Factor VIII Human genes 0.000 claims description 10
- 229960000301 factor viii Drugs 0.000 claims description 10
- 210000000130 stem cell Anatomy 0.000 claims description 10
- 101710169336 5'-deoxyadenosine deaminase Proteins 0.000 claims description 8
- 102000055025 Adenosine deaminases Human genes 0.000 claims description 8
- 102000012437 Copper-Transporting ATPases Human genes 0.000 claims description 8
- 108010022637 Copper-Transporting ATPases Proteins 0.000 claims description 8
- 102100037156 Gap junction beta-2 protein Human genes 0.000 claims description 8
- 208000015439 Lysosomal storage disease Diseases 0.000 claims description 8
- 208000007014 Retinitis pigmentosa Diseases 0.000 claims description 8
- 102100031176 Retinoid isomerohydrolase Human genes 0.000 claims description 8
- 108010039203 Tripeptidyl-Peptidase 1 Proteins 0.000 claims description 8
- 102100034197 Tripeptidyl-peptidase 1 Human genes 0.000 claims description 8
- 210000000577 adipose tissue Anatomy 0.000 claims description 8
- 210000002889 endothelial cell Anatomy 0.000 claims description 8
- 210000002216 heart Anatomy 0.000 claims description 8
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 8
- 210000004072 lung Anatomy 0.000 claims description 8
- 210000002569 neuron Anatomy 0.000 claims description 8
- 108020004707 nucleic acids Proteins 0.000 claims description 8
- 102000039446 nucleic acids Human genes 0.000 claims description 8
- 150000007523 nucleic acids Chemical class 0.000 claims description 8
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 8
- 108010054126 retinoid isomerohydrolase Proteins 0.000 claims description 8
- 239000012470 diluted sample Substances 0.000 claims description 7
- 102100022641 Coagulation factor IX Human genes 0.000 claims description 6
- 102100023804 Coagulation factor VII Human genes 0.000 claims description 6
- 241000702421 Dependoparvovirus Species 0.000 claims description 6
- 108010076282 Factor IX Proteins 0.000 claims description 6
- 108010023321 Factor VII Proteins 0.000 claims description 6
- 235000004279 alanine Nutrition 0.000 claims description 6
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims description 6
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims description 6
- 230000002950 deficient Effects 0.000 claims description 6
- 229960004222 factor ix Drugs 0.000 claims description 6
- 229940012413 factor vii Drugs 0.000 claims description 6
- 238000000338 in vitro Methods 0.000 claims description 6
- 238000001727 in vivo Methods 0.000 claims description 6
- 210000004185 liver Anatomy 0.000 claims description 6
- 238000011534 incubation Methods 0.000 claims description 5
- NMWKYTGJWUAZPZ-WWHBDHEGSA-N (4S)-4-[[(4R,7S,10S,16S,19S,25S,28S,31R)-31-[[(2S)-2-[[(1R,6R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42R,47R,53S,56S,59S,62S,65S,68S,71S,76S,79S,85S)-47-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-3-phenylpropanoyl]amino]-4-oxobutanoyl]amino]-3-carboxypropanoyl]amino]-18-(4-aminobutyl)-27,68-bis(3-amino-3-oxopropyl)-36,71,76-tribenzyl-39-(3-carbamimidamidopropyl)-24-(2-carboxyethyl)-21,56-bis(carboxymethyl)-65,85-bis[(1R)-1-hydroxyethyl]-59-(hydroxymethyl)-62,79-bis(1H-imidazol-4-ylmethyl)-9-methyl-33-(2-methylpropyl)-8,11,17,20,23,26,29,32,35,38,41,48,54,57,60,63,66,69,72,74,77,80,83,86-tetracosaoxo-30-propan-2-yl-3,4,44,45-tetrathia-7,10,16,19,22,25,28,31,34,37,40,49,55,58,61,64,67,70,73,75,78,81,84,87-tetracosazatetracyclo[40.31.14.012,16.049,53]heptaoctacontane-6-carbonyl]amino]-3-methylbutanoyl]amino]-7-(3-carbamimidamidopropyl)-25-(hydroxymethyl)-19-[(4-hydroxyphenyl)methyl]-28-(1H-imidazol-4-ylmethyl)-10-methyl-6,9,12,15,18,21,24,27,30-nonaoxo-16-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29-nonazacyclodotriacontane-4-carbonyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-3-carboxy-1-[[(2S)-1-[[(2S)-1-[[(1S)-1-carboxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid Chemical compound CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](Cc4ccccc4)NC3=O)[C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc3ccccc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N3CCC[C@H]3C(=O)N[C@@H](C)C(=O)N2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2c[nH]cn2)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)C(C)C)C(=O)N[C@@H](Cc2c[nH]cn2)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1)C(=O)N[C@@H](C)C(O)=O NMWKYTGJWUAZPZ-WWHBDHEGSA-N 0.000 claims description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 4
- 108010046716 3-Methyl-2-Oxobutanoate Dehydrogenase (Lipoamide) Proteins 0.000 claims description 4
- 241000702423 Adeno-associated virus - 2 Species 0.000 claims description 4
- 208000024806 Brain atrophy Diseases 0.000 claims description 4
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 claims description 4
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 claims description 4
- 101100029886 Caenorhabditis elegans lov-1 gene Proteins 0.000 claims description 4
- 108010078791 Carrier Proteins Proteins 0.000 claims description 4
- 108010059081 Cathepsin A Proteins 0.000 claims description 4
- 102000005572 Cathepsin A Human genes 0.000 claims description 4
- 208000026372 Congenital cystic kidney disease Diseases 0.000 claims description 4
- 108010069156 Connexin 26 Proteins 0.000 claims description 4
- 201000003883 Cystic fibrosis Diseases 0.000 claims description 4
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 claims description 4
- 102000003849 Cytochrome P450 Human genes 0.000 claims description 4
- 102000004127 Cytokines Human genes 0.000 claims description 4
- 108090000695 Cytokines Proteins 0.000 claims description 4
- 102000000311 Cytosine Deaminase Human genes 0.000 claims description 4
- 108010080611 Cytosine Deaminase Proteins 0.000 claims description 4
- 206010011878 Deafness Diseases 0.000 claims description 4
- 102100029588 Deoxycytidine kinase Human genes 0.000 claims description 4
- 108010033174 Deoxycytidine kinase Proteins 0.000 claims description 4
- 102000016607 Diphtheria Toxin Human genes 0.000 claims description 4
- 108010053187 Diphtheria Toxin Proteins 0.000 claims description 4
- 206010059866 Drug resistance Diseases 0.000 claims description 4
- 108010069091 Dystrophin Proteins 0.000 claims description 4
- 102000001039 Dystrophin Human genes 0.000 claims description 4
- 102000004190 Enzymes Human genes 0.000 claims description 4
- 108090000790 Enzymes Proteins 0.000 claims description 4
- 102000009024 Epidermal Growth Factor Human genes 0.000 claims description 4
- 101800003838 Epidermal growth factor Proteins 0.000 claims description 4
- 102000003951 Erythropoietin Human genes 0.000 claims description 4
- 108090000394 Erythropoietin Proteins 0.000 claims description 4
- 108010054265 Factor VIIa Proteins 0.000 claims description 4
- 108010014173 Factor X Proteins 0.000 claims description 4
- 108010071289 Factor XIII Proteins 0.000 claims description 4
- 201000006107 Familial adenomatous polyposis Diseases 0.000 claims description 4
- 102000013446 GTP Phosphohydrolases Human genes 0.000 claims description 4
- 108091006109 GTPases Proteins 0.000 claims description 4
- 102100023364 Ganglioside GM2 activator Human genes 0.000 claims description 4
- 101710201362 Ganglioside GM2 activator Proteins 0.000 claims description 4
- 108010021582 Glucokinase Proteins 0.000 claims description 4
- 102000030595 Glucokinase Human genes 0.000 claims description 4
- 102000004547 Glucosylceramidase Human genes 0.000 claims description 4
- 108010017544 Glucosylceramidase Proteins 0.000 claims description 4
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 4
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims description 4
- 101710191387 Guanylate cyclase 2D Proteins 0.000 claims description 4
- 102100027685 Hemoglobin subunit alpha Human genes 0.000 claims description 4
- 108091005902 Hemoglobin subunit alpha Proteins 0.000 claims description 4
- 102100021519 Hemoglobin subunit beta Human genes 0.000 claims description 4
- 108091005904 Hemoglobin subunit beta Proteins 0.000 claims description 4
- 102000002268 Hexosaminidases Human genes 0.000 claims description 4
- 108010000540 Hexosaminidases Proteins 0.000 claims description 4
- 101000954092 Homo sapiens Gap junction beta-2 protein Proteins 0.000 claims description 4
- 101001076292 Homo sapiens Insulin-like growth factor II Proteins 0.000 claims description 4
- 101001124388 Homo sapiens NPC intracellular cholesterol transporter 1 Proteins 0.000 claims description 4
- 102000018251 Hypoxanthine Phosphoribosyltransferase Human genes 0.000 claims description 4
- 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 claims description 4
- 102000004877 Insulin Human genes 0.000 claims description 4
- 108090001061 Insulin Proteins 0.000 claims description 4
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims description 4
- 102100025947 Insulin-like growth factor II Human genes 0.000 claims description 4
- 102000006992 Interferon-alpha Human genes 0.000 claims description 4
- 108010047761 Interferon-alpha Proteins 0.000 claims description 4
- 102000003996 Interferon-beta Human genes 0.000 claims description 4
- 108090000467 Interferon-beta Proteins 0.000 claims description 4
- 108010074328 Interferon-gamma Proteins 0.000 claims description 4
- 102000008070 Interferon-gamma Human genes 0.000 claims description 4
- 102000013462 Interleukin-12 Human genes 0.000 claims description 4
- 108010065805 Interleukin-12 Proteins 0.000 claims description 4
- 102000000588 Interleukin-2 Human genes 0.000 claims description 4
- 108010002350 Interleukin-2 Proteins 0.000 claims description 4
- 108090000978 Interleukin-4 Proteins 0.000 claims description 4
- 102000004388 Interleukin-4 Human genes 0.000 claims description 4
- 108010001831 LDL receptors Proteins 0.000 claims description 4
- 108010013563 Lipoprotein Lipase Proteins 0.000 claims description 4
- 102100022119 Lipoprotein lipase Human genes 0.000 claims description 4
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 claims description 4
- 102000004083 Lymphotoxin-alpha Human genes 0.000 claims description 4
- 108090000542 Lymphotoxin-alpha Proteins 0.000 claims description 4
- 108010006140 N-sulfoglucosamine sulfohydrolase Proteins 0.000 claims description 4
- 102100027661 N-sulphoglucosamine sulphohydrolase Human genes 0.000 claims description 4
- 102100029565 NPC intracellular cholesterol transporter 1 Human genes 0.000 claims description 4
- 108010025020 Nerve Growth Factor Proteins 0.000 claims description 4
- 102000015336 Nerve Growth Factor Human genes 0.000 claims description 4
- 102000004132 Ornithine aminotransferases Human genes 0.000 claims description 4
- 108090000691 Ornithine aminotransferases Proteins 0.000 claims description 4
- 102000007981 Ornithine carbamoyltransferase Human genes 0.000 claims description 4
- 101710198224 Ornithine carbamoyltransferase, mitochondrial Proteins 0.000 claims description 4
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 claims description 4
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 claims description 4
- 101800004937 Protein C Proteins 0.000 claims description 4
- 102000017975 Protein C Human genes 0.000 claims description 4
- 101710088575 Rab escort protein 1 Proteins 0.000 claims description 4
- 101710108890 Rab proteins geranylgeranyltransferase component A 1 Proteins 0.000 claims description 4
- 102100022881 Rab proteins geranylgeranyltransferase component A 1 Human genes 0.000 claims description 4
- 101800001700 Saposin-D Proteins 0.000 claims description 4
- 102000013275 Somatomedins Human genes 0.000 claims description 4
- 102000005890 Spectrin Human genes 0.000 claims description 4
- 108010019965 Spectrin Proteins 0.000 claims description 4
- 102000011971 Sphingomyelin Phosphodiesterase Human genes 0.000 claims description 4
- 108010061312 Sphingomyelin Phosphodiesterase Proteins 0.000 claims description 4
- 102000000019 Sterol Esterase Human genes 0.000 claims description 4
- 108010055297 Sterol Esterase Proteins 0.000 claims description 4
- 102000005262 Sulfatase Human genes 0.000 claims description 4
- 102000006601 Thymidine Kinase Human genes 0.000 claims description 4
- 108020004440 Thymidine kinase Proteins 0.000 claims description 4
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 4
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 4
- 102000009618 Transforming Growth Factors Human genes 0.000 claims description 4
- 108010009583 Transforming Growth Factors Proteins 0.000 claims description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 4
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 claims description 4
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 claims description 4
- 102100038413 UDP-N-acetylglucosamine-dolichyl-phosphate N-acetylglucosaminephosphotransferase Human genes 0.000 claims description 4
- 108010024501 UDPacetylglucosamine-dolichyl-phosphate acetylglucosamine-1-phosphate transferase Proteins 0.000 claims description 4
- 108010075653 Utrophin Proteins 0.000 claims description 4
- 102000011856 Utrophin Human genes 0.000 claims description 4
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 4
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 4
- 108010017070 Zinc Finger Nucleases Proteins 0.000 claims description 4
- 201000000761 achromatopsia Diseases 0.000 claims description 4
- 230000003213 activating effect Effects 0.000 claims description 4
- 208000031514 autosomal recessive nonsyndromic hearing loss 1A Diseases 0.000 claims description 4
- 210000000601 blood cell Anatomy 0.000 claims description 4
- 229940019700 blood coagulation factors Drugs 0.000 claims description 4
- 210000004556 brain Anatomy 0.000 claims description 4
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 claims description 4
- 102000002717 c-Mer Tyrosine Kinase Human genes 0.000 claims description 4
- 108010018804 c-Mer Tyrosine Kinase Proteins 0.000 claims description 4
- 210000003169 central nervous system Anatomy 0.000 claims description 4
- 210000001612 chondrocyte Anatomy 0.000 claims description 4
- 208000029664 classic familial adenomatous polyposis Diseases 0.000 claims description 4
- 235000018417 cysteine Nutrition 0.000 claims description 4
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 4
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 4
- 210000000188 diaphragm Anatomy 0.000 claims description 4
- 210000003027 ear inner Anatomy 0.000 claims description 4
- 210000003890 endocrine cell Anatomy 0.000 claims description 4
- 229940088598 enzyme Drugs 0.000 claims description 4
- 229940116977 epidermal growth factor Drugs 0.000 claims description 4
- 210000002919 epithelial cell Anatomy 0.000 claims description 4
- 229940105423 erythropoietin Drugs 0.000 claims description 4
- 210000001508 eye Anatomy 0.000 claims description 4
- 229940012414 factor viia Drugs 0.000 claims description 4
- 229940012426 factor x Drugs 0.000 claims description 4
- 229940012444 factor xiii Drugs 0.000 claims description 4
- 210000002950 fibroblast Anatomy 0.000 claims description 4
- 102000034356 gene-regulatory proteins Human genes 0.000 claims description 4
- 108091006104 gene-regulatory proteins Proteins 0.000 claims description 4
- 238000010362 genome editing Methods 0.000 claims description 4
- 230000002518 glial effect Effects 0.000 claims description 4
- 239000003102 growth factor Substances 0.000 claims description 4
- 230000010370 hearing loss Effects 0.000 claims description 4
- 231100000888 hearing loss Toxicity 0.000 claims description 4
- 208000016354 hearing loss disease Diseases 0.000 claims description 4
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 4
- 229940088597 hormone Drugs 0.000 claims description 4
- 239000005556 hormone Substances 0.000 claims description 4
- 230000002519 immonomodulatory effect Effects 0.000 claims description 4
- 230000002163 immunogen Effects 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 230000005764 inhibitory process Effects 0.000 claims description 4
- 229940125396 insulin Drugs 0.000 claims description 4
- 229960003130 interferon gamma Drugs 0.000 claims description 4
- 229940117681 interleukin-12 Drugs 0.000 claims description 4
- 229940028885 interleukin-4 Drugs 0.000 claims description 4
- 230000000968 intestinal effect Effects 0.000 claims description 4
- 210000004153 islets of langerhan Anatomy 0.000 claims description 4
- 210000003734 kidney Anatomy 0.000 claims description 4
- 210000004698 lymphocyte Anatomy 0.000 claims description 4
- 230000002132 lysosomal effect Effects 0.000 claims description 4
- 108020004999 messenger RNA Proteins 0.000 claims description 4
- 239000002184 metal Substances 0.000 claims description 4
- 229910052751 metal Inorganic materials 0.000 claims description 4
- -1 microdystrophin Proteins 0.000 claims description 4
- 229940053128 nerve growth factor Drugs 0.000 claims description 4
- 210000004498 neuroglial cell Anatomy 0.000 claims description 4
- 230000000508 neurotrophic effect Effects 0.000 claims description 4
- 210000002997 osteoclast Anatomy 0.000 claims description 4
- 210000000496 pancreas Anatomy 0.000 claims description 4
- 210000001428 peripheral nervous system Anatomy 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 208000030761 polycystic kidney disease Diseases 0.000 claims description 4
- 108091033319 polynucleotide Proteins 0.000 claims description 4
- 102000040430 polynucleotide Human genes 0.000 claims description 4
- 239000002157 polynucleotide Substances 0.000 claims description 4
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims description 4
- 229960000856 protein c Drugs 0.000 claims description 4
- 230000002207 retinal effect Effects 0.000 claims description 4
- 210000003079 salivary gland Anatomy 0.000 claims description 4
- 210000003491 skin Anatomy 0.000 claims description 4
- 150000003408 sphingolipids Chemical class 0.000 claims description 4
- 210000000952 spleen Anatomy 0.000 claims description 4
- 108060007951 sulfatase Proteins 0.000 claims description 4
- 208000011580 syndromic disease Diseases 0.000 claims description 4
- 210000002437 synoviocyte Anatomy 0.000 claims description 4
- 210000001550 testis Anatomy 0.000 claims description 4
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims description 4
- 210000001541 thymus gland Anatomy 0.000 claims description 4
- 230000024664 tolerance induction Effects 0.000 claims description 4
- 238000013518 transcription Methods 0.000 claims description 4
- 230000035897 transcription Effects 0.000 claims description 4
- 238000010361 transduction Methods 0.000 claims description 4
- 230000026683 transduction Effects 0.000 claims description 4
- 239000002753 trypsin inhibitor Substances 0.000 claims description 4
- 102000003390 tumor necrosis factor Human genes 0.000 claims description 4
- 239000000225 tumor suppressor protein Substances 0.000 claims description 4
- 241001529453 unidentified herpesvirus Species 0.000 claims description 4
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims description 4
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 3
- 230000001629 suppression Effects 0.000 claims description 3
- 206010053567 Coagulopathies Diseases 0.000 claims description 2
- 102100025907 Dyslexia-associated protein KIAA0319-like protein Human genes 0.000 claims description 2
- 102000008055 Heparan Sulfate Proteoglycans Human genes 0.000 claims description 2
- 229920002971 Heparan sulfate Polymers 0.000 claims description 2
- 101001076904 Homo sapiens Dyslexia-associated protein KIAA0319-like protein Proteins 0.000 claims description 2
- 101500025568 Homo sapiens Saposin-D Proteins 0.000 claims description 2
- 108090000054 Syndecan-2 Proteins 0.000 claims description 2
- 108700005077 Viral Genes Proteins 0.000 claims description 2
- 230000000890 antigenic effect Effects 0.000 claims description 2
- 208000015294 blood coagulation disease Diseases 0.000 claims description 2
- 230000004700 cellular uptake Effects 0.000 claims description 2
- 230000009852 coagulant defect Effects 0.000 claims description 2
- 239000003431 cross linking reagent Substances 0.000 claims description 2
- 238000007865 diluting Methods 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000037406 food intake Effects 0.000 claims description 2
- 238000001415 gene therapy Methods 0.000 claims description 2
- 210000003494 hepatocyte Anatomy 0.000 claims description 2
- 229940100689 human protein c Drugs 0.000 claims description 2
- 125000001165 hydrophobic group Chemical group 0.000 claims description 2
- 238000001802 infusion Methods 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 238000007917 intracranial administration Methods 0.000 claims description 2
- 238000007918 intramuscular administration Methods 0.000 claims description 2
- 210000005229 liver cell Anatomy 0.000 claims description 2
- 210000004738 parenchymal cell Anatomy 0.000 claims description 2
- 238000007920 subcutaneous administration Methods 0.000 claims description 2
- 230000009885 systemic effect Effects 0.000 claims description 2
- 239000000047 product Substances 0.000 claims 4
- 239000013066 combination product Substances 0.000 claims 1
- 229940127555 combination product Drugs 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161562795P | 2011-11-22 | 2011-11-22 | |
| US61/562,795 | 2011-11-22 | ||
| US201261639025P | 2012-04-26 | 2012-04-26 | |
| US61/639,025 | 2012-04-26 | ||
| US201261682019P | 2012-08-10 | 2012-08-10 | |
| US61/682,019 | 2012-08-10 | ||
| PCT/US2012/066380 WO2013078400A1 (en) | 2011-11-22 | 2012-11-21 | Virus vectors for highly efficient transgene delivery |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014534245A JP2014534245A (ja) | 2014-12-18 |
| JP2014534245A5 true JP2014534245A5 (enExample) | 2016-01-14 |
| JP6348064B2 JP6348064B2 (ja) | 2018-06-27 |
Family
ID=48470322
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014542594A Active JP6348064B2 (ja) | 2011-11-22 | 2012-11-21 | 効率の高いトランスジーン送達のためのウイルスベクター |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US10640785B2 (enExample) |
| EP (2) | EP2782596A4 (enExample) |
| JP (1) | JP6348064B2 (enExample) |
| AU (1) | AU2012340567B2 (enExample) |
| CA (1) | CA2856137A1 (enExample) |
| HK (1) | HK1202434A1 (enExample) |
| WO (1) | WO2013078400A1 (enExample) |
Families Citing this family (104)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100183558A1 (en) | 2008-10-17 | 2010-07-22 | Zhennan Lai | Safe lentiviral vectors for targeted delivery of multiple therapeutic molecules |
| WO2010138263A2 (en) | 2009-05-28 | 2010-12-02 | University Of Massachusetts | Novel aav 's and uses thereof |
| CN103501812A (zh) | 2011-04-29 | 2014-01-08 | 西莱克塔生物科技公司 | 用于过敏症治疗的致耐受性合成纳米载体 |
| US12024568B2 (en) | 2012-09-13 | 2024-07-02 | Cornell University | Treatment of brain cancers using central nervous system mediated gene transfer of monoclonal antibodies |
| EP4299741A3 (en) | 2012-12-12 | 2024-02-28 | The Broad Institute, Inc. | Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications |
| WO2014093709A1 (en) | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Methods, models, systems, and apparatus for identifying target sequences for cas enzymes or crispr-cas systems for target sequences and conveying results thereof |
| WO2014093701A1 (en) | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof |
| CN118370823A (zh) | 2013-05-03 | 2024-07-23 | 西莱克塔生物科技公司 | 用于降低的或增强的药效学作用的致耐受性合成纳米载体和治疗性大分子 |
| DK3011029T3 (da) | 2013-06-17 | 2020-03-16 | Broad Inst Inc | Administration, modificering og optimering af tandem-guidesystemer, fremgangsmåder og sammensætninger til sekvensmanipulering |
| ES2767318T3 (es) * | 2013-06-17 | 2020-06-17 | Broad Inst Inc | Suministro, modificación y optimización de sistemas, métodos y composiciones para generar modelos y actuar sobre enfermedades y trastornos de células posmitóticas |
| CN105492611A (zh) | 2013-06-17 | 2016-04-13 | 布罗德研究所有限公司 | 用于序列操纵的优化的crispr-cas双切口酶系统、方法以及组合物 |
| WO2014204727A1 (en) | 2013-06-17 | 2014-12-24 | The Broad Institute Inc. | Functional genomics using crispr-cas systems, compositions methods, screens and applications thereof |
| KR20160056869A (ko) | 2013-06-17 | 2016-05-20 | 더 브로드 인스티튜트, 인코퍼레이티드 | 바이러스 구성성분을 사용하여 장애 및 질환을 표적화하기 위한 crispr-cas 시스템 및 조성물의 전달, 용도 및 치료 적용 |
| EP3011031B1 (en) | 2013-06-17 | 2020-09-30 | The Broad Institute Inc. | Delivery and use of the crispr-cas systems, vectors and compositions for hepatic targeting and therapy |
| KR102445330B1 (ko) * | 2013-07-12 | 2022-09-19 | 더 칠드런스 호스피탈 오브 필라델피아 | Ａａｖ 벡터 및 항―ａａｖ （아데노-관련 바이러스） 중화 항체에 대한 검정 |
| MX2016001044A (es) * | 2013-07-22 | 2016-09-09 | The Children's Hospital Of Philadelphia | Aav variante y composiciones, metodos y usos para transferencia genica a celulas, organos y tejidos. |
| US20160355573A1 (en) * | 2013-09-05 | 2016-12-08 | Cornell University | Gene therapy for alzheimer's and other neurodegenerative diseases and conditions |
| CN106103705A (zh) | 2013-12-12 | 2016-11-09 | 布罗德研究所有限公司 | 核苷酸重复障碍中crispr‑cas系统的组合物和使用方法 |
| CA2932479A1 (en) | 2013-12-12 | 2015-06-18 | The Rockefeller University | Delivery, use and therapeutic applications of the crispr-cas systems and compositions for hbv and viral diseases and disorders |
| KR20250068794A (ko) | 2013-12-12 | 2025-05-16 | 더 브로드 인스티튜트, 인코퍼레이티드 | 게놈 편집을 위한 ｃｒｉｓｐｒ-ｃａｓ 시스템 및 조성물의 전달, 용도 및 치료적 응용 |
| WO2015089364A1 (en) | 2013-12-12 | 2015-06-18 | The Broad Institute Inc. | Crystal structure of a crispr-cas system, and uses thereof |
| WO2015089486A2 (en) | 2013-12-12 | 2015-06-18 | The Broad Institute Inc. | Systems, methods and compositions for sequence manipulation with optimized functional crispr-cas systems |
| WO2015089473A1 (en) | 2013-12-12 | 2015-06-18 | The Broad Institute Inc. | Engineering of systems, methods and optimized guide compositions with new architectures for sequence manipulation |
| US10577627B2 (en) | 2014-06-09 | 2020-03-03 | Voyager Therapeutics, Inc. | Chimeric capsids |
| US10781459B2 (en) * | 2014-06-20 | 2020-09-22 | University Of Florida Research Foundation, Incorporated | Methods of packaging multiple adeno-associated virus vectors |
| WO2016037162A1 (en) | 2014-09-07 | 2016-03-10 | Selecta Biosciences, Inc. | Methods and compositions for attenuating anti-viral transfer vector immune responses |
| WO2016054554A1 (en) * | 2014-10-03 | 2016-04-07 | University Of Massachusetts | Heterologous targeting peptide grafted aavs |
| WO2016055437A1 (en) * | 2014-10-06 | 2016-04-14 | Arthrogen B.V. | Aav-based gene therapy |
| EP3209311B1 (en) * | 2014-10-21 | 2024-03-06 | University of Massachusetts | Recombinant aav variants and uses thereof |
| SG11201703148TA (en) | 2014-11-05 | 2017-05-30 | Voyager Therapeutics Inc | Aadc polynucleotides for the treatment of parkinson's disease |
| GB201420139D0 (en) | 2014-11-12 | 2014-12-24 | Ucl Business Plc | Factor IX gene therapy |
| US10597660B2 (en) | 2014-11-14 | 2020-03-24 | Voyager Therapeutics, Inc. | Compositions and methods of treating amyotrophic lateral sclerosis (ALS) |
| MX2017006217A (es) | 2014-11-14 | 2018-05-02 | Voyager Therapeutics Inc | Polinucleotidos moduladores. |
| HK1245326A1 (zh) | 2014-12-12 | 2018-08-24 | Voyager Therapeutics, Inc. | 用於生产scaav的组合物和方法 |
| WO2016094867A1 (en) | 2014-12-12 | 2016-06-16 | The Broad Institute Inc. | Protected guide rnas (pgrnas) |
| WO2016106244A1 (en) | 2014-12-24 | 2016-06-30 | The Broad Institute Inc. | Crispr having or associated with destabilization domains |
| US10081659B2 (en) | 2015-04-06 | 2018-09-25 | The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services | Adeno-associated vectors for enhanced transduction and reduced immunogenicity |
| CA2982213C (en) | 2015-04-09 | 2022-10-18 | Cornell University | Gene therapy to prevent reactions to allergens |
| CA2987103A1 (en) * | 2015-05-28 | 2016-12-01 | Cornell University | Adeno-associated virus mediated delivery of c1ei as a therapy for angioedema |
| WO2016205759A1 (en) | 2015-06-18 | 2016-12-22 | The Broad Institute Inc. | Engineering and optimization of systems, methods, enzymes and guide scaffolds of cas9 orthologs and variants for sequence manipulation |
| KR102840885B1 (ko) | 2015-06-18 | 2025-07-30 | 더 브로드 인스티튜트, 인코퍼레이티드 | 표적외 효과를 감소시키는 crispr 효소 돌연변이 |
| PE20180675A1 (es) | 2015-06-23 | 2018-04-19 | Childrens Hospital Philadelphia | Factor ix modificado, y composiciones, metodos y usos para la transferencia de genes a celulas, organos y tejidos |
| WO2017007994A1 (en) | 2015-07-08 | 2017-01-12 | American Gene Technologies International Inc. | Hiv pre-immunization and immunotherapy |
| WO2017096162A1 (en) | 2015-12-02 | 2017-06-08 | Voyager Therapeutics, Inc. | Assays for the detection of aav neutralizing antibodies |
| US10137144B2 (en) | 2016-01-15 | 2018-11-27 | American Gene Technologies International Inc. | Methods and compositions for the activation of gamma-delta T-cells |
| CN116064678A (zh) | 2016-01-15 | 2023-05-05 | 美国基因技术国际有限公司 | 用于活化γ-δT细胞的方法和组合物 |
| US10888613B2 (en) | 2016-02-08 | 2021-01-12 | American Gene Technologies International Inc. | Method of producing cells resistant to HIV infection |
| WO2017156311A2 (en) | 2016-03-09 | 2017-09-14 | American Gene Technologies International Inc. | Combination vectors and methods for treating cancer |
| EP3448987A4 (en) | 2016-04-29 | 2020-05-27 | Voyager Therapeutics, Inc. | COMPOSITIONS FOR TREATING A DISEASE |
| US11326182B2 (en) | 2016-04-29 | 2022-05-10 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
| CN109152342A (zh) * | 2016-05-12 | 2019-01-04 | 布赖恩.P.汉利 | Crispr和其他基因疗法安全递送到人类和动物中的大部分体细胞 |
| MX2018014152A (es) | 2016-05-18 | 2019-03-28 | Voyager Therapeutics Inc | Composiciones y métodos para tratar la enfermedad de huntington. |
| KR20240056729A (ko) | 2016-05-18 | 2024-04-30 | 보이저 테라퓨틱스, 인크. | 조절성 폴리뉴클레오티드 |
| JP7173548B2 (ja) * | 2016-06-08 | 2022-11-16 | アメリカン ジーン テクノロジーズ インターナショナル インコーポレイテッド | 非組み込みウイルス送達系およびその関連方法 |
| IL300730A (en) | 2016-07-08 | 2023-04-01 | American Gene Tech Int Inc | Pre-HIV vaccine and immunotherapy |
| US11583562B2 (en) | 2016-07-21 | 2023-02-21 | American Gene Technologies International Inc. | Viral vectors for treating Parkinson's disease |
| US11298041B2 (en) | 2016-08-30 | 2022-04-12 | The Regents Of The University Of California | Methods for biomedical targeting and delivery and devices and systems for practicing the same |
| AU2017341849B2 (en) | 2016-10-13 | 2024-03-21 | University Of Massachusetts | AAV capsid designs |
| CA3040179A1 (en) | 2016-10-19 | 2018-04-26 | Adverum Biotechnologies, Inc. | Modified aav capsids and uses thereof |
| AU2017359342B2 (en) * | 2016-11-09 | 2022-02-17 | Intrexon Corporation | Frataxin expression constructs |
| EP3583220A4 (en) * | 2017-02-15 | 2021-07-07 | The University of North Carolina at Chapel Hill | PROCEDURES AND COMPOSITIONS FOR GENERAL TRANSFER IN THE VASCULAR SYSTEM |
| HUE072005T2 (hu) | 2017-03-11 | 2025-10-28 | Cartesian Therapeutics Inc | Gyulladásgátlókkal és immunszupresszánst tartalmazó szintetikus nanohordozókkal történõ kombinált kezeléssel összefüggõ eljárások és készítmények |
| WO2018187231A2 (en) | 2017-04-03 | 2018-10-11 | American Gene Technologies International Inc. | Compositions and methods for treating phenylketonuria |
| MX2019012113A (es) | 2017-04-14 | 2020-09-10 | Univ Nat Taiwan | Terapia génica para la deficiencia de la aadc. |
| AU2018261790B2 (en) | 2017-05-05 | 2024-10-03 | Voyager Therapeutics, Inc. | Compositions and methods of treating amyotrophic lateral sclerosis (ALS) |
| AU2018261003A1 (en) | 2017-05-05 | 2019-11-14 | Voyager Therapeutics, Inc. | Compositions and methods of treating Huntington's Disease |
| AR112057A1 (es) | 2017-05-22 | 2019-09-18 | Baxalta Inc | Vectores virales que codifican variantes de fix recombinantes con mayor expresión para la terapia génica de hemofilia b |
| JOP20190269A1 (ar) | 2017-06-15 | 2019-11-20 | Voyager Therapeutics Inc | بولي نوكليوتيدات aadc لعلاج مرض باركنسون |
| JP7229989B2 (ja) | 2017-07-17 | 2023-02-28 | ボイジャー セラピューティクス インコーポレイテッド | 軌道アレイガイドシステム |
| CA3075656A1 (en) | 2017-09-29 | 2019-04-04 | Voyager Therapeutics, Inc. | Rescue of central and peripheral neurological phenotype of friedreich's ataxia by intravenous delivery |
| WO2019079240A1 (en) | 2017-10-16 | 2019-04-25 | Voyager Therapeutics, Inc. | TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) |
| WO2019079242A1 (en) | 2017-10-16 | 2019-04-25 | Voyager Therapeutics, Inc. | TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) |
| WO2019126222A1 (en) * | 2017-12-18 | 2019-06-27 | Spark Therapeutics, Inc. | Adeno-associated virus (aav) vector lipid nanoparticle compositions and methods of use |
| US10610606B2 (en) | 2018-02-01 | 2020-04-07 | Homology Medicines, Inc. | Adeno-associated virus compositions for PAH gene transfer and methods of use thereof |
| BR112020015798A2 (pt) | 2018-02-01 | 2021-03-09 | Homology Medicines, Inc. | Composições de vírus adeno-associado para restaurar função de gene da pah e métodos de uso das mesmas |
| EP3755795A4 (en) | 2018-02-19 | 2022-07-20 | Homology Medicines, Inc. | Adeno-associated virus compositions for restoring f8 gene function and methods of use thereof |
| JP2021518342A (ja) * | 2018-03-13 | 2021-08-02 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアＴｈｅ Ｒｅｇｅｎｔｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃａｌｉｆｏｒｎｉａ | インスリンの経口送達のためのウイルス様ナノカプシド |
| AU2019247191A1 (en) | 2018-04-03 | 2020-10-15 | Ginkgo Bioworks, Inc. | Virus vectors for targeting ophthalmic tissues |
| SG11202009452WA (en) | 2018-04-03 | 2020-10-29 | Stridebio Inc | Antibody-evading virus vectors |
| JP2021519581A (ja) | 2018-04-03 | 2021-08-12 | ストライドバイオ，インコーポレイテッド | 抗体を回避するウイルスベクター |
| US12054724B2 (en) | 2018-04-10 | 2024-08-06 | President And Fellows Of Harvard College | AAV vectors encoding clarin-1 or GJB2 and uses thereof |
| EP3794126A1 (en) | 2018-05-15 | 2021-03-24 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of parkinson's disease |
| PL3802570T3 (pl) | 2018-06-06 | 2024-03-18 | The Regents Of The University Of California | Ulepszone wirusopodobne nanocząstki do podawania doustnego |
| US10842885B2 (en) | 2018-08-20 | 2020-11-24 | Ucl Business Ltd | Factor IX encoding nucleotides |
| GB201813528D0 (en) | 2018-08-20 | 2018-10-03 | Ucl Business Plc | Factor IX encoding nucleotides |
| AU2019346655B2 (en) | 2018-09-28 | 2025-03-13 | Voyager Therapeutics, Inc. | Frataxin expression constructs having engineered promoters and methods of use thereof |
| WO2020102753A1 (en) * | 2018-11-16 | 2020-05-22 | Spark Therapeutics, Inc. | In vitro assay for detecting enhancers and inhibitors of adeno associated virus (aav) vector transduction and/or detecting or quantitating anti-aav binding antibodies |
| AR118465A1 (es) | 2019-03-21 | 2021-10-06 | Stridebio Inc | Vectores de virus adenoasociados recombinantes |
| ES2928689T3 (es) | 2019-04-12 | 2022-11-22 | Freeline Therapeutics Ltd | Sistema de plásmidos |
| AU2020272557A1 (en) | 2019-04-12 | 2021-12-09 | Ascend Gene And Cell Therapies Ltd | Plasmid system |
| US20200405824A1 (en) * | 2019-06-26 | 2020-12-31 | University Of Washington | Use of ribonucleotide reductase alone or in combination with micro-dystrophin to treat duchenne muscular dystrophy striated muscle disease |
| EP4007768A4 (en) * | 2019-08-01 | 2023-11-15 | The University of North Carolina at Chapel Hill | COMPOSITIONS AND METHODS FOR BINDING ANTIBODIES AND INHIBITING NEUTRALIZING ANTIBODIES |
| US11155835B2 (en) | 2019-08-19 | 2021-10-26 | The Catholic University Of America | Prokaryotic-eukaryotic hybrid viral vector for delivery of large cargos of genes and proteins into human cells |
| CA3157700A1 (en) | 2019-10-17 | 2021-04-22 | Stridebio, Inc. | Adeno-associated viral vectors for treatment of niemann-pick disease type c |
| WO2021089856A1 (en) | 2019-11-08 | 2021-05-14 | Horama | Modified adeno-associated virus vectors and delivery thereof into the central nervous system |
| CA3161367A1 (en) * | 2019-12-10 | 2021-06-17 | Homology Medicines, Inc. | Adeno-associated virus compositions and methods of use thereof |
| TW202140791A (zh) | 2020-01-13 | 2021-11-01 | 美商霍蒙拉奇醫藥公司 | 治療苯酮尿症之方法 |
| TW202208632A (zh) | 2020-05-27 | 2022-03-01 | 美商同源醫藥公司 | 用於恢復ｐａｈ基因功能的腺相關病毒組成物及其使用方法 |
| CA3189878A1 (en) | 2020-08-19 | 2022-02-24 | Colin O'BANION | Adeno-associated virus vectors for treatment of rett syndrome |
| US12129287B2 (en) | 2020-09-14 | 2024-10-29 | President And Fellows Of Harvard College | Recombinant adeno associated virus encoding clarin-1 and uses thereof |
| GB202016254D0 (en) | 2020-10-13 | 2020-11-25 | Freeline Therapeutics Ltd | Plasmid system |
| WO2024259079A2 (en) * | 2023-06-14 | 2024-12-19 | Fractyl Health, Inc. | Gene therapies for metabolic disorders |
| EP4628576A1 (en) | 2024-04-07 | 2025-10-08 | Ascend Advanced Therapies GmbH | Microrna molecules for use in methods for improving recombinant aav production |
| WO2025238067A1 (en) | 2024-05-15 | 2025-11-20 | Ascend Advanced Therapies Gmbh | Novel vector system for aav production |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1202962A (en) | 1982-10-19 | 1986-04-08 | David P. Clifford | Substituted n-phenyl-n'-benzoyl ureas and their use as insecticides and acaricides |
| US4965188A (en) | 1986-08-22 | 1990-10-23 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| WO1998010088A1 (en) | 1996-09-06 | 1998-03-12 | Trustees Of The University Of Pennsylvania | An inducible method for production of recombinant adeno-associated viruses utilizing t7 polymerase |
| JP2002531418A (ja) | 1998-12-03 | 2002-09-24 | アビジェン， インコーポレイテッド | アデノ随伴ウイルスの薬学処方物における使用のための賦形剤、およびそれにより構成される薬学処方物 |
| US20080220015A1 (en) | 2001-08-03 | 2008-09-11 | Nokad, S.A. | Method of modulating neutralizing antibodies formation in mammals, and uses thereof in gene therapy, animal trangenesis and in functional inactivation of endogenous proteins |
| US20040028654A1 (en) | 2002-03-22 | 2004-02-12 | Board Of Regents, The University Of Texas System | Protamine-adenoviral vector complexes and methods of use |
| NZ536274A (en) | 2002-05-01 | 2008-04-30 | Univ Florida | Improved rAAV expression systems for genetic modification of specific capsid proteins |
| JP4566129B2 (ja) | 2003-02-17 | 2010-10-20 | 扶桑薬品工業株式会社 | 新規ウイルスベクター |
| EP1751275B1 (en) | 2004-06-01 | 2017-08-16 | Avigen, Inc. | Compositions and methods to prevent aav vector aggregation |
| DE602005015994D1 (de) * | 2004-09-29 | 2009-09-24 | Childrens Memorial Hospital | siRNA-VERMITTELTES GEN-SILENCING VON ALPHA-SYNUKLEIN |
| US20090317417A1 (en) * | 2006-04-28 | 2009-12-24 | The Trustees Of The University Of Pennsylvania | Modified AAV Vectors Having Reduced Capsid Immunogenicity and Use Thereof |
| JP6373763B2 (ja) * | 2012-02-17 | 2018-08-22 | ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィアＴｈｅ Ｃｈｉｌｄｒｅｎ’Ｓ Ｈｏｓｐｉｔａｌ Ｏｆ Ｐｈｉｌａｄｅｌｐｈｉａ | Ａａｖベクター成分、及び、細胞、臓器並びに組織への遺伝子導入のための方法 |
-
2012
- 2012-11-21 US US14/360,151 patent/US10640785B2/en active Active
- 2012-11-21 EP EP12851878.4A patent/EP2782596A4/en not_active Withdrawn
- 2012-11-21 WO PCT/US2012/066380 patent/WO2013078400A1/en not_active Ceased
- 2012-11-21 CA CA2856137A patent/CA2856137A1/en active Pending
- 2012-11-21 HK HK15103023.8A patent/HK1202434A1/xx unknown
- 2012-11-21 EP EP18209899.6A patent/EP3539568A1/en active Pending
- 2012-11-21 AU AU2012340567A patent/AU2012340567B2/en active Active
- 2012-11-21 JP JP2014542594A patent/JP6348064B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014534245A5 (enExample) | ||
| Zhao et al. | Viral vector‐based gene therapies in the clinic | |
| JP6373763B2 (ja) | Ａａｖベクター成分、及び、細胞、臓器並びに組織への遺伝子導入のための方法 | |
| JP2022065003A (ja) | パルボウイルスベクターの高められた送達のための改変キャプシドタンパク質 | |
| US10640785B2 (en) | Virus vectors for highly efficient transgene delivery | |
| Cao et al. | Adenoviral vectors for gene replacement therapy | |
| Gorecki | Prospects and problems of gene therapy: an update | |
| KR20160033217A (ko) | 변종 ａａｖ 및 조성물, 세포, 기관 및 조직으로의 유전자 전이를 위한 방법 및 용도 | |
| KR20180091863A (ko) | 임상적 사용에 적합한 무혈청 현탁 세포 배양 시스템에서 재조합 아데노-관련 바이러스(aav) 벡터를 생성하기 위한 확장가능한 방법 | |
| JP2015509711A5 (enExample) | ||
| WO2015124546A1 (en) | Aav vectors for the treatment of ischemic and non-ischemic heart disease | |
| JP2016517278A (ja) | スタッファー／フィラーポリヌクレオチド配列を含むベクターおよびその使用方法 | |
| JP2008523813A (ja) | キメラベクター | |
| WO2014063753A1 (en) | Hyper-active factor ix vectors for liver-directed gene therapy of hemophilia 'b' and methods and use thereof | |
| Geng et al. | Viral and non-viral vectors in gene therapy: current state and clinical perspectives | |
| EP4509606A1 (en) | Nucleic acid construct for treating hereditary coagulation factor deficiency and use thereof | |
| IL298772A (en) | Coding-optimized nucleic acid encoding the SMN1 protein and its use | |
| Geiger et al. | Vectors for pulmonary gene therapy | |
| JP4219335B2 (ja) | インターフェロンβのような分泌タンパク質をコードする遺伝子を使用する治療のための方法および組成物 | |
| Ziady et al. | Current prospects for gene therapy of cystic fibrosis | |
| US20170065685A1 (en) | Serca2 therapeutic compositions and methods of use | |
| US6165754A (en) | Method of expressing an exogenous nucleic acid | |
| Hausl et al. | Development of adenovirus hybrid vectors for Sleeping Beauty transposition in large mammals | |
| Usman et al. | Recombinant adeno-associated viruses as a gene delivery vehicle for the use in molecular medicine | |
| JP2005502585A (ja) | 治療的核酸の送達を増強するための方法 |